Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, showing ...

The University of Oxford has launched what it says is the world's first phase I clinical trial of a vaccine specifically ...

New biotech Avere Therapeutics has taken a fast-track to becoming a publicly listed company by merging with NextCure, with a ...

A study has shown that, for people living with advanced cancer, a simple, weekly remote check-in with their care team can ...

AstraZeneca has continued its pipeline-boosting deal spree in China with a $1.5 billion agreement that gives it global rights ...

As the hype builds around radiopharmaceuticals, Novartis’s Pluvicto (lutetium PSA) remains one of the few that’s actually made it to market. In a conversation at ASCO 2026, Dr Fred Saad of the ...

After a delay, Eisai and Biogen have won FDA approval for their new subcutaneous formulation of Alzheimer's disease therapy ...

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade, particularly for patients whose tumours harbour mutations in the epidermal ...

GSK's pivotal AZUR-1 trial of cancer immunotherapy Jemperli, as a way to delay or eliminate surgery in pre-operative rectal ...

EU pharmaceutical safety advisers have said that commonly used contraceptives may carry a small risk of a type of brain ...

A large-scale trial has been launched, with $100 million in backing, to explore whether lifestyle changes coupled with GLP-1 ...

Hundreds of researchers at the Institute of Cancer Research (ICR) in London have held historic strikes across sites in Sutton ...